The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.
 
Denise A. Yardley
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Immunomedics (Inst); IntegraConnect (Inst); Novartis (Inst); Stemline Therapeutics (Inst)
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Biomarin (Inst); Biothera (Inst); Dana Farber Cancer Hospital (Inst); Eisai (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Incyte (Inst); Innocrin Pharma (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Polyphor (Inst); Stemline Therapeutics (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); US Oncology Network (Inst)
 
Michael Untch
Honoraria - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Genzyme (Inst); Gilead Sciences (Inst); Lilly (Inst); Medac (Inst); MSD Oncology (Inst); Myriad Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); Seagen (Inst); Stemline Therapeutics (Inst)
 
Carlos H. Barrios
Stock and Other Ownership Interests - MedSIR; Tummi
Honoraria - Adium Pharma; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Consulting or Advisory Role - AstraZeneca; Libbs; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Covance (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); ICON Clinical Research (Inst); INC Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Servier (Inst); Syneos Health (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Aditya Bardia
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Kevin Kalinsky
Employment - EQRx (I); GRAIL (I)
Stock and Other Ownership Interests - EQRx (I); GRAIL (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship - Genentech; Immunomedics
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Stephen K. L. Chia
Honoraria - AstraZeneca; Gilead Sciences; Lilly; Merck; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)
 
Alistair E. Ring
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche UK; Seagen
Research Funding - AstraZeneca (Inst)
 
Nicholas Patrick McAndrew
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; GoodRx; Novartis
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Loxo (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
 
Vicente Valero
Honoraria - AstraZeneca; Genentech/Roche; Novartis
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Novartis
Travel, Accommodations, Expenses - Genentech/Roche
 
Manuel Ruiz-Borrego
Honoraria - Novartis; pfizer; Roche/Genentech
Consulting or Advisory Role - Puma Biotechnology; Roche
 
Rodrigo Fresco
Other Relationship - Employed by TRIO. TRIO is contracted by Novartis as CRO conducting the NATALEE trial
 
Eleanor Sum
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Yogesh Chattar
Employment - Novartis
 
Sorcha Waters
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - AstraZeneca; Daiichi-Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; Viatris; Zuelligpharma
Consulting or Advisory Role - Gilead Sciences; Roche/Genentech; Seagen; West German Study Group (I)
Speakers' Bureau - EPG Communication; Medscape; Springer Healthcare
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)